MEDILIFE FUNCTION
ActiveSummary
MEDILIFE FUNCTION has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €84,658 and a net result of €40,220. The computed 12-month bankruptcy probability is 0.6% (low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 06-11-2023 Normal situation
- Activity
- No activity registered in the KBO
- Establishment unit
- 2.352.152.604 1190 Vorst, since 06-11-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 10-03-2026
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.6%
- Gross margin
- €50,252
- ▼ 3.6%
- Turnover
- ≈ €150,000
- estimated
- Profit
- €40,220
- ▼ 0.5%
- Equity
- €84,658
- ▲ 90.5%
- Total assets
- €109,287
- ▲ 90.3%
Score breakdownraises riskFounded in 2023lowers riskLiquidity: current ratio 4.17, cash €31,928Size: total assets €109,287Equity €84,658 (77.5% of total assets)Show the evidence
Checked score
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 81% of them on solvency, 72% on liquidity, 90% on profitability and 92% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 2 accounts on average 8 days after the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 24-06-2026 at the NBB all 2 filings
Every figure per financial year
The operating result for 2025 is 6% lower than in 2024.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Investments
| Item | 2024 | 2025 |
|---|---|---|
| Tangible fixed assets | €1,938 | €6,288 |
| Depreciation and write-downs of the year | €307 | €1,257 |
Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €307 | €1,257 | ▲ 309% |
| Other operating charges640/8 | €81 | €328 | ▲ 303% |
| Gross operating margin9900 | €52,116 | €50,252 | ▼ 3.6% |
| Operating profit (loss)9901 | €51,727 | €48,666 | ▼ 5.9% |
| Financial income75/76B | €769 | €2,497 | ▲ 225% |
| Recurring financial income75 | €769 | €2,497 | ▲ 225% |
| Financial charges65/66B | €21 | €117 | ▲ 467% |
| Recurring financial charges65 | €21 | €117 | ▲ 467% |
| Profit (loss) for the period before taxes9903 | €52,476 | €51,047 | ▼ 2.7% |
| Income taxes67/77 | €12,037 | €10,827 | ▼ 10.1% |
| Profit (loss) for the period9904 | €40,439 | €40,220 | ▼ 0.5% |
| Profit (loss) for the period to be appropriated9905 | €40,439 | €40,220 | ▼ 0.5% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €57,428 | €109,287 | ▲ 90.3% |
| Fixed assets21/28 | €1,631 | €6,661 | ▲ 308% |
| Tangible fixed assets22/27 | €1,631 | €6,661 | ▲ 308% |
| Plant, machinery and equipment23 | €1,631 | €3,407 | ▲ 109% |
| Furniture and vehicles24 | - | €3,255 | - |
| Current assets29/58 | €55,797 | €102,625 | ▲ 83.9% |
| Amounts receivable within one year40/41 | €32,273 | €54,353 | ▲ 68.4% |
| Other amounts receivable41 | €32,273 | €54,353 | ▲ 68.4% |
| Current investments50/53 | €10,000 | €14,000 | ▲ 40.0% |
| Cash at bank and in hand54/58 | €12,755 | €31,928 | ▲ 150% |
| Deferred charges and accrued income490/1 | €769 | €2,345 | ▲ 205% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €57,428 | €109,287 | ▲ 90.3% |
| Equity10/15 | €44,439 | €84,658 | ▲ 90.5% |
| Contributions10/11 | €4,000 | €4,000 | = |
| Reserves13 | €40,439 | €80,658 | ▲ 99.5% |
| Distributable reserves133 | €40,439 | €80,658 | ▲ 99.5% |
| Amounts payable17/49 | €12,990 | €24,629 | ▲ 89.6% |
| Amounts payable within one year42/48 | €12,990 | €24,629 | ▲ 89.6% |
| Trade debts44 | €952 | €799 | ▼ 16.1% |
| Suppliers440/4 | €952 | €799 | ▼ 16.1% |
| Taxes, remuneration and social security45 | €12,037 | €23,829 | ▲ 98.0% |
| Taxes450/3 | €12,037 | €23,829 | ▲ 98.0% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | €40,439 | €40,220 | ▼ 0.5% |
| + Depreciation and write-downs630 | €307 | €1,257 | ▲ 309% |
| Operating cash flow (approximation) | €40,746 | €41,477 | ▲ 1.8% |
| Investment in fixed assets (approximation) | - | -€6,288 | - |
| Change in cash | - | €19,172 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 39,278 companies had the same profile as MEDILIFE FUNCTION has now. Two years later, 95.8% were still going and 1.8% had gone bankrupt.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of MEDILIFE FUNCTION itself: 0.6% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for MEDILIFE FUNCTION. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Board & ownership
Directors
Owners and capital
Shareholders
- NEZRI Jonathan 100 shares (100%) · in cash
Capital transactions
- 08-11-2023 Incorporation · €4,000 · 100 shares
Articles of association
Board and representation
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “1, engagement écrit déontologie médicale et secret professionnel”
Capital, shares and profit
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “À défaut société mise en liquidation, opposition au refus d'agrément entre vifs devant président tribunal de l'entreprise siégeant comme en…”
- Share issue ruleThe articles set how and by whom new shares are issued.
- “Nécessite modification statuts, seuls médecins inscrits Ordre des Médecins peuvent être titulaires”
Articles of association, deed of 08-11-2023 (in French)
Network & group
MEDILIFE FUNCTION shares no director with another company.
Companies at the same address
2 other companiesConnections & network
1 current directorThe network starts from the directors of MEDILIFE FUNCTION. Every other company they run is a node.
Timeline
Acts, filings and financial milestones
08-11
Gazette deed
IncorporationStarting capital €4,000 · Appointment: NEZRI Jonathan (director) · Founder · Kind of shares6 points ▸
- Incorporation, “MEDILIFE FUNCTION” (deed in French)
- Founder, NEZRI Jonathan
- Kind of shares, “nominatives”, 100 (deed in French)
- Director appointment, NEZRI Jonathan (director (not named in the articles))
- Founding capital, €4,000
- Pre-incorporation commitments, “takeover, engagements souscrits par le fondateur pour le compte de la société en formation” (deed in French)
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
MEDILIFE FUNCTION was incorporated on 6 November 2023 as a private limited company by one natural person, with a starting capital of €4,000.12 NEZRI Jonathan is director of the company, appointed in the act of 08-11-2023.2 The company has filed 2 sets of annual accounts, the latest for financial year 2025.3
Company details
Register details
Identity
KBO recordRegistered office and establishments
Invoicing and payment
Financial year and general meeting
Accounts at the NBBSites & property
Buildings and parcels at the address
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 21384D0087/00F009 | Brussels | 1,082 m² | 1 · 404 m² | 16.4 m · 5 |